| Literature DB >> 26935652 |
Céline Z Duval1,2,3, Yannick Goumon4, Véronique Kemmel5,6, Jürgen Kornmeier7,8, André Dufour9, Olivier Andlauer10, Pierre Vidailhet1, Pierrick Poisbeau4, Eric Salvat4,11, André Muller4,11, Ayikoé G Mensah-Nyagan5, Catherine Schmidt-Mutter2, Anne Giersch1.
Abstract
Patients with schizophrenia have often been described as insensitive to nociceptive signals, but objective evidence is sparse. We address this question by combining subjective behavioral and objective neurochemical and neurophysiological measures. The present study involved 21 stabilized and mildly symptomatic patients with schizophrenia and 21 control subjects. We applied electrical stimulations below the pain threshold and assessed sensations of pain and unpleasantness with rating scales, and Somatosensory Evoked Potentials (SEPs/EEG). We also measured attention, two neurochemical stress indices (ACTH/cortisol), and subjective VEPs/EEG responses to visual emotional stimuli. Our results revealed that, subjectively, patients' evaluations do not differ from controls. However, the amplitude of EEG evoked potentials was greater in patients than controls as early as 50 ms after electrical stimulations and beyond one second after visual processing of emotional pictures. Such responses could not be linked to the stress induced by the stimulations, since stress hormone levels were stable. Nor was there a difference between patients and controls in respect of attention performance and tactile sensitivity. Taken together, all indices measured in patients in our study were either heightened or equivalent relative to healthy volunteers.Entities:
Mesh:
Year: 2016 PMID: 26935652 PMCID: PMC4776095 DOI: 10.1038/srep22542
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Early and late pain-related SEP measurements at the sites Cz and Fz, with mean amplitudes of the evoked potentials (with standard errors).
| mean (SEM) controls | F | Df | P | Cohen’s d | ||
|---|---|---|---|---|---|---|
| Cz | ||||||
| P50 | ||||||
| Main effect: Group | ||||||
| 1300μA | 3.98 (1.3) | 1.3 (0.6) | 3.62 | 1,34 | 0.07 | – |
| 1800μA | 3.65 (1.1) | 1.25 (0.3) | 4.17 | 1,40 | < 0.05 | 0.62 |
| N1 | ||||||
| Main effect: Group | ||||||
| 1300μA | −4.9 (1.7) | −3.69 (1) | 0.38 | 1,34 | 0.54 | – |
| 1800μA | −4.22 (1.7) | −1.56 (0.6) | 3.15 | 1,40 | 0.08 | – |
| P1 | ||||||
| Main effect: Group | ||||||
| 1300μA | 6.15 (1.1) | 3.28 (1.3) | 2.93 | 1,34 | 0.1 | – |
| 1800μA | 6.28 (1.2) | 4.74 (0.9) | 1.13 | 1,40 | 0.29 | – |
| P1* | ||||||
| Main effect: Group | ||||||
| 1300μA | 3.87 (1.6) | −0.88 (2.1) | 3.25 | 1,34 | 0.08 | – |
| 1800μA | 4.97 (2) | −0.27 (1.2) | 6.47 | 1,40 | < 0.05 | 0.7 |
| N2 | ||||||
| Main effect: Group | ||||||
| 1300μA | −6.2 (1.4) | −6.59 (2.1) | 0.02 | 1,34 | 0.88 | – |
| 1800μA | −6.33 (1.3) | −6.04 (1.2) | 0.02 | 1,40 | 0.88 | – |
| P2 | ||||||
| Main effect: Group | ||||||
| 1300μA | 16.27 (1.2) | 15.52 (1.5) | 0.14 | 1,34 | 0.71 | – |
| 1800μA | 11.71 (1.4) | 11.68 (1.1) | 0.0003 | 1,40 | 0.99 | – |
| Fz | ||||||
| P50 | ||||||
| Main effect: Group | ||||||
| 1300μA | 4.6 (1.4) | 1.81 (0.8) | 2.94 | 1,34 | 0.1 | – |
| 1800μA | 4.16 (1.1) | 1.72 (0.4) | 4.4 | 1,40 | < 0.05 | 0.67 |
| P1* | ||||||
| Main effect: Group | ||||||
| 1300μA | 5.34 (1.6) | −1.1 (1.8) | 7.22 | 1,34 | < 0.05 | 0.9 |
| 1800μA | 6.51 (2.2) | −1.2 (1.2) | 9.18 | 1,40 | < 0.005 | 0.94 |
The statistics of group effects are detailed for each evoked potential following the 1300 and 1800 μA stimulations at Cz, and the P50 and P1* at Fz. The p significance levels were set at p < 0.05, and the Cohen’s d value shows the effect size.
Figure 1Representation of the pain-related SEP in patients with schizophrenia (red) and control subjects (blue) after mild painful electrical stimulations at 1800μV.
(a) overall distribution of SEP traces on a schematic skull with 32 electrodes (b) SEPs at electrode Cz (c) amplitude of the 4 main peaks, in patients (red) and controls (blue).
Figure 2Representations of the visual ERP in patients with schizophrenia (red) and control subjects (blue) after visual stimulations with pictures with different emotional valences.
(A) ERP traces of patients and controls at electrode Cz, averaged over all picture types. (B) Time course of the LPP amplitude in each group based on individual peak analysis.
Mean ERP peak amplitude (with standard errors) in the two groups after picture presentation.
| mean (SEM) patients | mean (SEM) controls | F | Df | P | Cohen’s d | |
|---|---|---|---|---|---|---|
| Fz | ||||||
| P1 (0.2–0.4 s) | ||||||
| Main effect: Group (μV) | 0.54 (1.0) | 0.95 (1.0) | 0.14 | 1,36 | 0.71 | – |
| N2 (0.2–0.4 s) | ||||||
| Main effect: Group (μV) | −8.1 (1.0) | −8.13 (1.2) | .0005 | 1,36 | 0.98 | – |
| LPP (1.0–1.2 s) | ||||||
| Main effect: Group (μV) | 5.55 (1.0) | 3.5 (1.1) | 4.34 | 1,36 | < 0.05 | 0.57 |
| LPP (1.2–1.4 s) | ||||||
| Main effect: Group (μV) | 5.36 (0.8) | 2.83 (1.0) | 7.48 | 1,36 | < 0.05 | 0.62 |
| LPP (1.4–1.6 s) | ||||||
| Main effect: Group (μV) | 4.67 (0.8) | 1.91 (1.1) | 9.26 | 1,36 | < 0.005 | 0.64 |
| Cz | ||||||
| P1 (0.2–0.4 s) | ||||||
| Main effect: Group (μV) | 2.04 (0.7) | 2.03 (0.8) | 0.00002 | 1,36 | 0.99 | – |
| N2 (0.2–0.4 s) | ||||||
| Main effect: Group (μV) | −6.3 (0.9) | −6.07 (1.1) | 0.03 | 1,36 | 0.87 | – |
| LPP (1.0–1.2 s) | ||||||
| Main effect: Group (μV) | 3.5 (0.8) | 2.08 (1.0) | 3.66 | 1,36 | 0.06 | – |
| LPP (1.2–1.4 s) | ||||||
| Main effect: Group (μV) | 3.36 (0.8) | 1.46 (0.9) | 6.15 | 1,36 | < 0.05 | 0.53 |
| LPP (1.4–1.6 s) | ||||||
| Main effect: Group (μV) | 3.48 (0.5) | 1.05 (0.6) | 9.26 | 1,36 | < 0.005 | 1.04 |
The ERP results are averaged and combined over all three picture types. The statistics of group effects are detailed for evoked potential at Cz, and Fz. The p significance levels were set at p < 0.05, and the Cohen’s d value shows the effect size.
Demographic and clinical data about the participants, including the average number of painful events in their medical history.
| Patients | Controls | |
|---|---|---|
| Gender (M/F) | 16/5 | 16/5 |
| Age (mean ± SD) | 37.7 ± 9.2 | 37.4 ± 10.7 |
| Years of education (mean ± SD) | 13.3 ± 2.3 | 13.1 ± 2.3 |
| Medication (typical/atypical/no medication) | 5/14/2 | ─ |
| Dose of chlorpromazine equivalents | 244 mg/day | ─ |
| Anti-Parkinsonian treatment (tropatepine) | 4 | ─ |
| Number of hospitalizations in psychiatry | 3.3 ± 3 | ─ |
| Mean age at disease onset | 25.2 ± 5 | ─ |
| Mean disease duration | 12.2 ± 7 | ─ |
| Outpatients/Inpatients | 20/1 | ─ |
| PANSS positive symptoms (mean ± SD) | 17.5 ± 5.9 | ─ |
| PANSS negative symptoms (mean ± SD) | 21.9 ± 8.2 | ─ |
| PANSS general symptoms (mean ± SD) | 38.2 ± 10.4 | ─ |
| PANSS total (mean ± SD) | 77.6 ± 10.1 | ─ |
| Mean number of medical painful events (mean ± SD) | 0.8 ± 0.8 | 0.8 ± 1 |
| Mean number of surgeries (mean ± SD) | 1.2 ± 0.9 | 0.6 ± 0.6 |
| Mean number of accidents (mean ± SD) | 1 ± 0.9 | 1.4 ± 1.2 |
| Mean number of suicide attempts (mean ± SD) | 0.4 ± 0.7 | 0 |
Figure 3Experimental procedure performed on Day 2.
For the sake of simplicity, we have not reported the results of the attentional tasks (AX-CPT), because they do not provide any relevant information. Early application of the catheter avoided any interference with blood sampling by the needle prick. The blood samples were taken twice, before and after the series of pain stimulations. The test involving emotional pictures was conducted at the end of the protocol, after the second blood sample was taken. About a quarter of an hour elapsed therefore between the last series of electrical stimulations and the presentation of the pictures.